Edition:
India

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

2.93USD
17 Nov 2017
Change (% chg)

$0.22 (+8.12%)
Prev Close
$2.71
Open
$2.77
Day's High
$2.95
Day's Low
$2.77
Volume
84,020
Avg. Vol
82,825
52-wk High
$32.00
52-wk Low
$2.15

Select another date:

Fri, Oct 27 2017

BRIEF-Tandem Diabetes Care reports Q3 sales of $27 million

* Tandem Diabetes Care reports third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

BRIEF-Empery Asset Management reports 5.63 pct passive stake in Tandem Diabetes Care

* Empery Asset Management Lp reports 5.63 pct passive stake in Tandem Diabetes Care Inc as of Oct 13 - SEC filing‍​ Source text: (http://bit.ly/2hSFBfg) Further company coverage:

BRIEF-Tandem Diabetes Care sees Q3 sales of about $26.5 mln to $27.5 mln

* Sees Q3 sales about $26.5 million to $27.5 million - sec filing

BRIEF-Tandem Diabetes Care announces proposed public offering of common stock

* Tandem Diabetes Care announces proposed underwritten public offering of common stock, Series A warrants and Series B warrants Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care‍ shareholders approv reverse stock split

* Tandem Diabetes Care Inc- ‍ shareholders subsequently approved reverse stock split at a ratio of 1-for-10​ Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps

* Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care begins enrollment for 1st touchscreen insulin pump with PGLS

* Tandem Diabetes Care begins enrollment in pivotal trial for first touchscreen insulin pump with predictive low glucose suspend (PLGS)

BRIEF-Tandem Diabetes Care Q2 net loss per share $0.44

* Tandem Diabetes Care reports second quarter 2017 financial results

Select another date: